Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(55.6%)

Phase 1

3(33.3%)

Phase 3

1(11.1%)

9Total

Phase 2(5)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03254368Phase 2Completed

Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes

Role: lead

NCT02179151Phase 3Terminated

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

Role: lead

NCT02063295Phase 2Completed

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Role: lead

NCT01818921Phase 2Completed

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Role: lead

NCT01666691Phase 2Completed

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

Role: lead

NCT02324491Phase 2Terminated

An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT01507077Phase 1Completed

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Role: lead

NCT01028261Phase 1Completed

Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

Role: lead

NCT01372761Phase 1Completed

Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers

Role: lead

All 9 trials loaded